Effects of diquafosol sodium 3% versus hyaluronic acid 0.1% in patients with dry eye disease after cataract surgery: A single-center, randomized, controlled trial

Inomata Takenori0 个研究点目标入组 42 人开始时间: 2021年4月6日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Women over 20 years old
•2) Patients who have undergone cataract surgery in both eyes within 14 days of completing the first eye
•3) 3.Patients diagnosed with DED after cataract surgery (More than 13 points of J-OSDI total score and tear film breakup time less than 5 seconds)
•4) 4.Patients who, after receiving a full explanation of their participation in the study and with a full understanding of the study, have given written consent of their own free will to participate in the study
•5) In case of inability to self-administer eye drops, patients with a caregiver willing to and able to assist in administration of the assigned eye drop as part of the study

•1) Patients with dry eye diagnosed prior to cataract surgery (J-OSDI of 13 points or higher and tear layer breakup time of 5 seconds or less)
•2) Patients with active eye infections
•3) Spring catarrh patients
•4) Patients with recurrent corneal erosions
•5) Patients with hereditary corneal disease
•6) Patients with physical irritation of the cornea and conjunctiva due to wear and tear or laxity of the ocular conjunctiva
•7) Patients who cannot or will not be able to discontinue ophthalmic medications other than concomitantly restricted medications (including all prescription and OTC medications) from the initial screening examination to the end of the study medication eye drop
•8) Patients who cannot stop using their contact lenses from the start of the screening examination until the end of the study drug eye drop
•9) Patients after corneal refractive surgery
•10) Patients with a teardrop plug or a history of surgical teardrop closure
•11) Patients with hypersensitivity to the components of the study drug and the study's test product
•12) Patients using glaucoma eye drops
•13) Patients with systemic diseases, suchas diabetes mellitus, thyroid disease. Autoimmune diseases, and atopic dermatitis
•14) Other patients who are deemed by the principal investigator to be unsuitable as research subjects

发起方

Inomata Takenori